Ann: $1.43M R&D rebate received, page-35

I sold all of mine on that spike - but have applied for everything I can get/afford, even was able to apply for some as a shortfall placement. If I get as much as I have sought I hope to flog most of the heads at some stage and keep all of the options, otherwise will keep more heads if a small allocation. Hoping to generate a free carry, getting this so cheaply. Then live or die by the trial results. This really is a bargain IMO, with the co getting results of two phase two trials in HIV, one randomised double blinded, and priced at a market cap of $25m. And the two trials will cost way less than $5m.

I reckon if a couple of previously ART/cART non-responding patients have a result of undetectable HIV, the market cap might quickly be around $250m. Statistical significance with such a small number of patients is unlikely, but depending on the trial design possible with near perfect results. If that were to happen, I believe there could be a drug worth roughly $80k usd for a cure or $20k USD per annum maintenance. That would be a result of near Gilead's Sovaldi proportions, and eventually worth (5?) billions once approved. Still a long way to go however.

The market sometimes makes big mistakes. See what happens.

GL to us!!!